MATTHEW SCHOLZ

Matthew is a serial entrepreneur with a background in gene therapy and computer security. He has founded or co-founded five biotechnology companies and has played an integral role in the development of several advanced therapeutics, including three first-in-class treatment modalities. He is the author of dozens of patents covering innovations ranging from novel transfection technologies, immune cell programming, in vivo production of therapeutic proteins, senolytics, longevity, and oncology.